Amit Etkin says Alto Neuro is trying to use machine learning to understand signals from the complexity of the brain, and the company is also embedding AI in its clinical trials in order to collect as much information from the field as possible. He also walks us through the company's program.

He discusses the importance of interest rates to high risk sectors like biotech, and comment on how our sector has not performed lately like other "risk-on" assets have. Plus, explaining his job of helping CEOs of NYSE listed companies understand the economic and capital markets environment.

Note: The NYSE is a sponsor of BiotechTV

Sam Sinai talks about how capsids are being more precisely designed today, which is allowing drug developers to better target them to different organs and to improve their efficiency. Plus, why he believes AI will help make cell and gene therapies reach more patients in the future.

He highlights recent M&A, but also notes how the sector has not been reliant on deals like it has in the past. Plus, discussing how Sarepta's wild ride has not led to contagion, and previewing what key data events are upcoming.

CEO Abbas Kazimi and President of R&D Peter Tummino discuss how AI integrates into their discovery and clinical development work, and walk us through some of the company's current programs.

He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the field in general, including what orforglipron might mean for the oral therapy space and why Metsera believes in an oral peptide.

CEO Lyn Baranowski describes the therapy and demonstrates the nebulizer that delivers it, and explains how Avalyn's method is designed increase the dose patients can take vs oral therapies and, therefore, increase the therapeutic value.

He discusses the science behind NLRP3, and describes why he thinks NodThera's brain penetration differentiates it from other programs from pharma and other companies. The weight loss program is a oral therapy that doesn't require titration and hasn't shown GI tolerability side effects.

He describes the benefits of prime editing, walks us through human proof-of-concept data that was announced in a patient with Chronic Granulomatous Disease, and explains the rationale to focus on Wilson's Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis, and the company's CAR-T partnership with Bristol Myers Squibb.

He describes why Kailera chose to in-license a GLP1/GIP specifically, and describes where he sees this asset placing in the competitive landscape based on this data. Plus, commentary on CMC, business development, oral therapies, and more.